Best Agrolife

Best Agrolife reported a challenging FY26, with consolidated revenue declining by 31% YoY to ₹1,257 crore from ₹1,814 crore in FY25. Gross margin percentage, however, slightly improved to 30% from 29% in the previous year. EBITDA for FY26 fell by 50% to ₹100 crore, resulting in an EBITDA margin of 8% compared to 11% in FY25. Profit After Tax (PAT) saw a significant decline of 87% to ₹9 crore, with PAT margin at 1%. Q4 FY26 was particularly weak, with revenue at ₹156 crore (down 43% YoY), negative EBITDA of ₹27 crore, and negative PAT of ₹37 crore.

The company faced significant headwinds in FY26, including adverse climatic conditions, unseasonal weather, and uneven pest incidences, which impacted sales in key regions like Haryana and Punjab. Elevated channel inventory levels, weak dealer liquidity, and volatility in raw material prices further exacerbated the situation. In response, management focused on strengthening long-term fundamentals, implementing calibrated pricing actions, and controlling inventory and expenses. A conscious decision was made in March to hold inventory rather than sell at lower prices, impacting Q4 revenue but aiming to protect future profitability.

Best Agrolife continued its focus on building a stronger patented portfolio. In FY26, the company launched three patented products: Bestman, Fetagen, and Shot Down, which received positive farmer acceptance. The R&D efforts yielded 7 combination patents and 1 nano urea patent. For FY27, the company plans to launch additional patented products including Fluzam, Midcotin, Cubax Power Extra, and Trishanku, and produce at least 4 new generation molecules at its Gajraula facility, reinforcing its commitment to innovation and 'Atmanirbhar' manufacturing.

A key operational priority was working capital optimization and inventory reduction. Inventory levels were successfully reduced from ₹958 crore in FY24 to ₹773 crore in FY25, and further to ₹651 crore as of March 31, 2026. This reduction was achieved through tighter procurement planning, calibrated production schedules, and rationalization of slower-moving inventory. To mitigate rising input costs, the company implemented two rounds of price increases in April and May 2026, expecting these interventions to support profitability from Q1 FY27 onwards.

An analyst raised concerns about the company's balance sheet, highlighting ₹500 crores in receivables against ₹1000 crores in sales, with over ₹200 crores outstanding for more than 6 months. Management clarified that high receivables in March are seasonal, with collections expected by June-July. They stated that doubtful debts over the last 3 years were less than 0.7% and that banks understand this cyclical pattern. The company also noted its bank facility utilization is 85-90%, with 10% still available, and is leveraging government funding for additional liquidity.

Best Agrolife is actively pursuing international registrations, with two registrations in Mexico in final approval stages, progress in Sri Lanka for patented molecules, and a first registration in Thailand. Plans are also underway to establish a subsidiary in Brazil. Domestically, the company is addressing the surge in counterfeits for popular products like Ronfen by introducing high-security holograms. Additionally, new labels will display the mode of action (IRAC, HRAC, FRAC) to help farmers combat pest resistance effectively.

Despite the challenging external environment, Best Agrolife believes it is structurally better positioned for FY27. The company expects improved profitability from Q1 FY27 due to calibrated pricing actions, new bio products, and patented products. The strategy includes strengthening the B2B segment by manufacturing active ingredients and technicals for external sales, not just captive consumption, aiming for a more fixed payment schedule and improved top and bottom lines. Management did not provide specific numerical guidance for FY27 but expressed confidence in a better year ahead.